Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 868 participants.
Also called NCT03061214
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 868 participants
- Sponsor
- Registry
-
NCT03061214
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Brazil, China, Hong Kong SAR China, South Africa, South Korea, Taiwan, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03061214. Randomized; double masking; primary purpose treatment. Start 2017-08-28 (actual); primary completion 2019-03-14 (actual). Results posted on 2020-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- Acronym
- SUSTAIN
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide 0.5 mg
- Intervention (Drug)
- Semaglutide 1.0 mg
- Intervention (Drug)
- Sitagliptin placebo
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Semaglutide placebo 0.5 mg
- Intervention (Drug)
- Semaglutide placebo 1.0 mg
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03061214- Content hash
1906b8345a71ab671bce60fd330daa2fe211349b3bdbc8880808389442c2cd0a